Top Alliance

TopAlliance Biosciences is a clinical-stage biopharmaceutical company and the North American research and development arm of Shanghai Junshi Biosciences. The company focuses on the discovery and development of innovative therapies, particularly in oncology, metabolic diseases, and inflammation. Its flagship product, Loqtorzi (toripalimab), is a PD-1 inhibitor that has received FDA approval for the treatment of recurrent or metastatic nasopharyngeal carcinoma. TopAlliance manages a diverse pipeline of monoclonal antibodies and other biologics, leveraging its global R&D infrastructure to bring novel treatments to the US and international markets.